Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
U.S. Food and Drug Administration Awards Additional Funding for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
CoTec Holdings Corp. Announces Final Closing of Private Placement of Unsecured Convertible Debentures, Total Raise of $20 Million
